VTRS

VTRS is the classic 'cash-rich, growth-poor' generic pharma. The FY2025 headline is ugly — a -$3.51B net loss, -18.7% operating margin, and -23.9% ROE — but the loss is overwhelmingly non-cash: operating cash flow held essentially flat at $2.32B (+0.6%) against $2.80B of D&A, and the MD&A explicitly flags 'goodwill or impairment charges or other losses' plus enterprise-wide restructuring as the drivers. Strip the write-downs and this is still a business that converts revenue into ~$1.9B of free cash flow (OCF $2.32B less $379M capex) on a $19.2B market cap — roughly a 10% FCF yield — while returning capital via a $0.12 quarterly dividend (~2.9% yield, held steady through 2024–2025) and $501M of buybacks with ~$1.0B still authorized. At a 1.3x P/S and mid-single-digit FCF multiple, the price is not demanding.

The problem is the top line. Revenue has fallen every year since the Upjohn merger — $17.8B (2021) → $16.2B → $15.4B → $14.7B → $14.3B — a durable ~3-8% annual erosion that no amount of cost-cutting has yet arrested, and gross profit fell a steeper -10.8% in FY2025, so mix and pricing are working against the company (generic loss-of-exclusivity is named directly as a risk). Retained earnings have flipped negative to -$388M, meaning cumulative distributions/losses now exceed cumulative earnings. Balance sheet is serviceable but not comfortable: $14.4B of total debt against just $1.32B cash and 1.53x liabilities/equity, and current-portion debt ballooned to $1.93B — a near-term maturity the company must roll or repay against thin liquidity.